Pendant fatty acid imaging agents
View Patent ↗The disclosure provides pendant fatty acid compounds for use in diagnostic imaging, (particularly the cardiovascular system), as well as kits comprised of the same. The disclosure also provides for a method administering a imaging agent with a high specificity for the myocardium.
1. The imaging agent represented by the structure 3:
wherein R 3 is H or alkyl;
R 7 is
wherein the wavy line indicates the point of attachment to the rest of the molecule;
R 8 is selected from the group consisting of ═O (oxo), H, OH, alkoxy, or O-alkyl;
m is an integer between 0 and 12 inclusive;
n is an integer between 0 and 12 inclusive;
p is an integer between 0 and 12 inclusive; wherein a stereochemical configuration of a compound represented by 3 may be R or S, at the stereocenters; or a mixture of these configurations;
or a pharmaceutically acceptable salt or amide thereof.
2. The imaging agent of claim 1 , wherein R 8 is ═O (oxo).
3. A composition comprising the imaging agent of claim 1 , wherein the stereochemical configuration of the imaging agent is a R-stereoisomer, and the composition is of more than about 75% isomeric purity.
4. A composition comprising the imaging agent of claim 1 , wherein the stereochemical configuration of the imaging agent is a S-stereoisomer, and the composition is of more than about 75% isomeric purity.
5. The imaging agent represented by the structure 4:
wherein
R 7 is
wherein the wavy line indicates the point of attachment to the rest of the molecule;
R 8 is selected from the group consisting of ═O (oxo), H, OH, alkoxy, or O-alkyl;
m is an integer selected from 0 to 12;
p is an integer selected from 0, 1, 2, 4, 6 or 8, wherein a stereochemical configuration of a compound represented by structure 4 may be R or S, at the stereocenters; or a mixture of these configurations;
or a pharmaceutically acceptable salt or amide thereof.
6. The imaging agent of claim 5 , wherein m is selected from 0, 1, or 2.
7. A composition comprising the imaging agent of claim 5 , wherein the stereochemical configuration of the imaging agent is a R-stereoisomer, and the composition is of more than about 75% isomeric purity.
8. A composition comprising the imaging agent of claim 6 , wherein the stereochemical configuration of the imaging agent is a S-stercoisomer, and the composition is of more than about 75% isomeric purity.